A Phase II Study (TACTI-002) in First-Line Metastatic Non–small Cell Lung Carcinoma Investigating Eftilagimod Alpha (soluble LAG-3 Protein) and Pembrolizumab: Updated Results from a PD-L1 Unselected Population.
JOURNAL OF CLINICAL ONCOLOGY（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined